Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.

TitleIntegration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.
Publication TypeJournal Article
Year of Publication2015
AuthorsLim Y, Gondek L, Li L, Wang Q, Ma H, Ma H, Chang E, Huso DL, Foerster S, Marchionni L, McGovern K, Watkins DNeil, Peacock CD, Levis M, Smith BDouglas, Merchant AA, Small D, Matsui W
JournalSci Transl Med
Volume7
Issue291
Pagination291ra96
Date Published2015 Jun 10
ISSN1946-6242
KeywordsAnimals, Cell Compartmentation, Cell Line, Tumor, Cell Proliferation, Cell Survival, Disease Progression, Drug Synergism, fms-Like Tyrosine Kinase 3, Gene Duplication, Hedgehog Proteins, Humans, Kruppel-Like Transcription Factors, Leukemia, Myeloid, Acute, Mice, Mutant Proteins, Myeloproliferative Disorders, Niacinamide, Nuclear Proteins, Phenylurea Compounds, Receptors, G-Protein-Coupled, Signal Transduction, Smoothened Receptor, Sorafenib, STAT5 Transcription Factor, Stem Cells, Veratrum Alkaloids, Zinc Finger Protein Gli2
Abstract

FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations resulting in constitutive kinase activity are common in acute myeloid leukemia (AML) and carry a poor prognosis. Several agents targeting FLT3 have been developed, but their limited clinical activity suggests that the inhibition of other factors contributing to the malignant phenotype is required. We examined gene expression data sets as well as primary specimens and found that the expression of GLI2, a major effector of the Hedgehog (Hh) signaling pathway, was increased in FLT3-ITD compared to wild-type FLT3 AML. To examine the functional role of the Hh pathway, we studied mice in which Flt3-ITD expression results in an indolent myeloproliferative state and found that constitutive Hh signaling accelerated the development of AML by enhancing signal transducer and activator of transcription 5 (STAT5) signaling and the proliferation of bone marrow myeloid progenitors. Furthermore, combined FLT3 and Hh pathway inhibition limited leukemic growth in vitro and in vivo, and this approach may serve as a therapeutic strategy for FLT3-ITD AML.

DOI10.1126/scitranslmed.aaa5731
Alternate JournalSci Transl Med
PubMed ID26062848
PubMed Central IDPMC4644635
Grant ListR01 CA090668 / CA / NCI NIH HHS / United States
R21CA155733 / CA / NCI NIH HHS / United States
P30 DK090868 / DK / NIDDK NIH HHS / United States
R01 CA150142 / CA / NCI NIH HHS / United States
UL1 TR001079 / TR / NCATS NIH HHS / United States
P30CA006973 / CA / NCI NIH HHS / United States
P30 CA006973 / CA / NCI NIH HHS / United States
R01 CA127574 / CA / NCI NIH HHS / United States
T32 HL007525 / HL / NHLBI NIH HHS / United States
P30DK090868 / DK / NIDDK NIH HHS / United States
R21 CA155733 / CA / NCI NIH HHS / United States
R01CA127574 / CA / NCI NIH HHS / United States
K08 CA154975 / CA / NCI NIH HHS / United States
R01 CA174951 / CA / NCI NIH HHS / United States
R01CA174951 / CA / NCI NIH HHS / United States
R01CA090668 / CA / NCI NIH HHS / United States
UL1TR001079 / TR / NCATS NIH HHS / United States
Related Faculty: 
Luigi Marchionni, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700